肝胆舒康胶囊结合阿德福韦酯治疗终末期乙型肝炎临床观察  

Clinical observation of combined Adefovir Dipivoxil and "Gandan Shukang Capsule" in treating terminal hepatitis B

作　　者：郑金莉[1] 

机构地区：[1]中国人民解放军第118医院肝病科,浙江温州325000

出　　处：《上海中医药杂志》2011年第12期52-53,共2页Shanghai Journal of Traditional Chinese Medicine

基　　金：浙江省温州市科技局基金项目(Y20090335)

摘　　要：目的观察肝胆舒康胶囊治疗终末期乙型病毒性肝炎的临床疗效。方法将106例终末期乙型肝炎患者随机分为对照组(51例)和治疗组(55例);对照组采用口服阿德福韦酯片治疗,治疗组口服阿德福韦酯片和肝胆舒康胶囊,疗程均为48周。结果治疗后,两组血清HA、LN、PCⅢ均较治疗前明显降低(P<0.01),且治疗组低于对照组(P<0.05);治疗组门静脉内径和脾厚度缩小(P<0.05),且较对照组小(P<0.05)。结论阿德福韦酯片联合肝胆舒康胶囊治疗终末期乙型病毒性肝炎疗效确切。Objective To observe the clinical efficacy of combined Adefovir Dipivoxil and ＂Gandan Shukang Capsule＂ in the treatment of terminal hepatitis B. Methods One hundred and six subjects were randomly divided into control group and treatment group. Fifty-one cases in control group were treated with Adefovir Dipivoxil and 55 cases in treatment group were treated with Adefovir Dipivoxi and ＂Gandan Shukang Capsule＂, with a Course of 48 weeks. Results After treatment, the contents of serum HA, LN and PC III were reduced in both groups （P 〈 0. 01 ）, with lower contents in the treatment group than in the control group （ P 〈 0. 05 ） ; the diameter of portal vein and splenic thickness were diminished in treatment group （ P 〈 0. 05 ） , smaller than those in the control group （ P 〈 0.05 ）. Conclusion Combined Adefovir Dipivoxil and ＂Gandan Shukang Capsule＂ is quite effective for terminal hepatitis B.

关 键 词：终末期乙型病毒性肝炎 肝纤维化 肝胆舒康胶囊 

分 类 号：R512.62[医药卫生—内科学]